Filter by
Filter by
Proton Therapy in Supradiaphragmatic Lymphoma: Predicting Treatment-Related Mortality to Help Optimize Patient Selection.
Published in the Red Journal, this study identified patients who benefit most from PBT in terms of predicted 30-year absolute mortality risks (AMR30) from...
Executive Summary of Clinical and Technical Guidelines for Esophageal Cancer Proton Beam Therapy From the Particle Therapy Co-Operative Group Thoracic and Gastrointestinal Subcommittees.
In this guideline document, the dosimetric data and clinical evidence of PBT for esophageal cancer (EC) was summarized and evaluated. The clinical outcome data...
IBA Proton Therapy Conference at ASTRO 2019
AMIT MAITY, MD, PhD Executive Vice-Chair Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia "Proton FLASH Radiation...
Randomized Clinical Trial Comparing Proton Beam Radiation Therapy with Transarterial Chemoembolization for Hepatocellular Carcinoma
A randomized trial comparing proton therapy with transarterial chemoembolization (TACE) for hepatocellular carcinoma, reported a trend toward improved local...
Clinical outcomes and toxicities of proton radiotherapy for gastrointestinal neoplasms: a systematic review
A systematic review examined clinical outcomes and toxicities of proton therapy for gastrointestinal neoplasms. The findings include that proton therapy was...
FLASH Radiotherapy Using Single-Energy Proton PBS Transmission Beams for Hypofractionation Liver Cancer: Dose and Dose Rate Quantification.
Another study by the group from New York Proton Center (ProBeam) assessed the feasibility of FLASH RT using single-energy transmission PBS plans of 4.5 Gy × 15...
Treating gastrointestinal malignancy with proton therapy
The improved dosimetry with proton therapy enables greater sparing of normal tissues...
Dose-escalated PT with elective nodal irradiation and concomitant chemotherapy for unresectable, borderline resectable, or medically inoperable pancreatic cancer
This study by the Jacksonville group reported treatment outcomes of proton therapy for pancreatic cancer. 15 patients received 40.5 GyRBE in 18 fractions to the...